SAN DIEGO & TOKYO--(BUSINESS WIRE)-- Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that the first presentation of interim data from a global multi-center Phase 2 study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback